Start with the question, not the folder
A leukemia second opinion is only as useful as the question it answers. Before assembling documents, write down what you want the reviewing hematologist to address. Common questions include whether the diagnosis and subtype are fully characterised, whether the proposed treatment fits the current disease phase, what alternatives exist if the first plan has not worked, and whether a transplant assessment is relevant. Each of these needs different records, so naming the question first prevents you from sending an undifferentiated archive.
Leukemia is not one disease. Acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia and chronic lymphocytic leukemia are assessed with different tests and treated along different lines. Even within one subtype, risk classification depends on genetic and molecular findings. A reviewer cannot give a meaningful opinion on a plan without knowing which subtype is being treated and what evidence supports it.
Keep the question short and concrete. "Is the current diagnosis complete, and does the proposed plan match the disease risk group?" is more useful than "Please review everything." A focused question also helps the hospital decide which specialist should look at the file. The hospital, not the patient or a coordinator, decides whether a records-based review is appropriate and what it can establish.
The core clinical records a hematologist will look for
The backbone of any leukemia second opinion is the laboratory and pathology record. Blood count reports should be dated and sequential, because the trend over time often matters as much as a single result. Include the full blood count with differential, and any peripheral blood film reports. If a flow cytometry study was done on blood or marrow, include the full report rather than a summary line.
Bone marrow examination reports are central. Send the original pathology or hematology report, including the morphological description, the blast percentage and any immunohistochemistry. If the marrow was reported at a local laboratory and later reviewed elsewhere, include both versions. A second opinion may involve pathology re-review, and the reviewer needs to see what was originally reported and by whom, not a retyped summary.
Cytogenetic and molecular results are often decisive for risk classification and treatment choice. Include karyotype reports, fluorescence in situ hybridisation results, and any polymerase chain reaction or next-generation sequencing panels, with the gene list and variant details. If a test was ordered but the report is pending, say so rather than leaving a gap the reviewer cannot interpret.
Treatment records complete the picture. Provide the regimen names, doses, cycle dates and responses, plus any measurable residual disease results. If treatment was stopped or changed, note why. Include relevant imaging only where it relates to the leukemia question, such as a report documenting organ involvement or infection during treatment.
How to organise the file so it can actually be read
A large file is not the same as a useful file. Put documents in chronological order within categories: laboratory results, pathology and marrow reports, genetic and molecular reports, treatment summaries, and current clinical status. Give each document its original date and the name of the issuing laboratory or hospital. Where a report is in another language, a short factual translation of the key findings helps, but keep the original alongside it.
Write a one-page cover summary yourself or with your treating team. It should state the diagnosis as recorded, the date of diagnosis, the current disease status, treatments received with dates, the current plan and the question you want answered. This is not a substitute for the records; it is a map. Reviewers can then go straight to the documents that matter.
Do not send passport numbers, payment details or a complete lifetime medical archive at first contact. A brief summary is enough to start. After initial contact, the team can explain how to share records securely and what format is preferred. Ask whether reports should be sent as searchable PDFs and whether original-language documents are acceptable.
Keep a personal index of what you have sent and when. If a report is missing, the reviewer can ask for it specifically. A clear index also helps if you later need the same file for a different hospital or for your own records.
What a records-based opinion can and cannot settle
A records-based hematology opinion can comment on whether the diagnostic work-up appears complete, whether the reported risk classification is consistent with the documents, and what treatment options are recognised for that disease phase. It can identify missing tests that would change the assessment. It cannot examine you, repeat a marrow, or confirm how you would tolerate a specific regimen.
Suitability for any treatment, including intensive chemotherapy or transplant, remains a decision for the treating hospital after its own assessment. A review of records does not establish eligibility for a clinical trial, transplant access or availability of a particular therapy in China. Those are separate questions that depend on the hospital, the current protocol and the patient's clinical state. Ask the receiving team directly rather than treating a positive records opinion as confirmation of access.
Timing matters clinically. If the patient is unwell, has a rising blast count, active infection or other urgent problem, local emergency care takes priority over assembling an overseas second opinion. A records review is for decisions that can wait for a considered answer. Do not delay urgent treatment to complete a file.
Questions to put to the reviewing team
Once the file is with a hematology team, ask what the review actually covered. Useful questions include: which documents were available and which were missing; whether the diagnosis and subtype are supported by the reported tests; whether any additional pathology, cytogenetic or molecular review is recommended; and what the reviewer sees as the main uncertainties. Ask whether the opinion is based only on records or whether an in-person assessment is needed before any plan can be confirmed.
Ask about the practical route as well. Does the hospital need the original slides or blocks for pathology re-review, and how are they shipped? Are there language or report-format requirements? What does the hospital's written plan or quote include, and what would be arranged separately? These are administrative questions the hospital or coordinating team should answer specifically for your case, not general rules that apply everywhere in China.
If the first opinion and the second opinion differ, ask both teams to explain the basis for their recommendation. A difference may reflect new evidence, a different reading of the same test, or a different view of what the patient can tolerate. Understanding why the recommendations diverge is often more valuable than choosing one opinion outright.
A practical next step
Begin with a short summary: the diagnosis as recorded, the date, the current phase, treatments received and the single question you want answered. ChinaSpecialistCare's free initial case review checks the available diagnosis, records and main question, identifies missing information and suggests a relevant next step. This is not a diagnosis or a promise of acceptance, and an initial enquiry does not require buying a proxy consultation.
If a records-based specialist opinion is then appropriate, the hospital's hematology team decides what it can assess from the documents. You can read more about the leukemia treatment pathway in China in the acute leukemia treatment reference, and about blood disorder and blood cancer care in the hematology specialty section. Keep your own copy of everything you send, and confirm in writing what the hospital has received and what it still needs.
Sources & scope of this guide
References and official service information relevant to this guide.
- payment
- blood disorder and blood cancer care
- Related treatment reference
- Acute Myeloid Leukemia Treatment - NCI
- Acute Lymphoblastic Leukemia Treatment - NCI
This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.
